$3.51
At close: Apr 28 EDT
$3.56
0.051.42%
Pre-Market: 5:10 AM EDT
Comments
Loading...
Iovance Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:IOVA | Benzinga
Iovance Biotherapeutics Inc has a consensus price target of $17.63 based on the ratings of 17 analysts. The high is $32 issued by HC Wainwright & Co. on February 28, 2025. The low is $5 issued by Barclays on April 14, 2025. The 3 most-recent analyst ratings were released by Goldman Sachs, Barclays, and Truist Securities on April 17, 2025, April 14, 2025, and March 3, 2025, respectively. With an average price target of $12 between Goldman Sachs, Barclays, and Truist Securities, there's an implied 237.08% upside for Iovance Biotherapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Barclays
Truist Securities
Chardan Capital
Baird
1calculated from analyst ratings
Analyst Ratings for Iovance Biotherapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/17/2025 | Buy Now | 349.44% | Goldman Sachs | Andrea Tan40% | $18 → $16 | Maintains | Buy | Get Alert |
| 04/14/2025 | Buy Now | 40.45% | Barclays | Peter Lawson42% | $22 → $5 | Maintains | Overweight | Get Alert |
| 03/03/2025 | Buy Now | 321.35% | Truist Securities | Asthika Goonewardene41% | $25 → $15 | Maintains | Buy | Get Alert |
| 03/03/2025 | Buy Now | 433.71% | Goldman Sachs | Andrea Tan40% | $22 → $19 | Maintains | Buy | Get Alert |
| 03/03/2025 | Buy Now | 742.7% | Chardan Capital | Geulah Livshits45% | $34 → $30 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 461.8% | Baird | Michael Ulz61% | $24 → $20 | Maintains | Outperform | Get Alert |
| 02/28/2025 | Buy Now | 68.54% | Piper Sandler | Joseph Catanzaro43% | $7.5 → $6 | Maintains | Neutral | Get Alert |
| 02/28/2025 | Buy Now | 798.88% | HC Wainwright & Co. | Joseph Pantginis45% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2025 | Buy Now | 110.67% | Piper Sandler | Joseph Catanzaro43% | $10 → $7.5 | Maintains | Neutral | Get Alert |
| 11/06/2024 | Buy Now | 798.88% | HC Wainwright & Co. | Joseph Pantginis45% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | 377.53% | UBS | David Dai26% | → $17 | Initiates | → Buy | Get Alert |
| 08/12/2024 | Buy Now | 798.88% | HC Wainwright & Co. | Joseph Pantginis45% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 07/29/2024 | Buy Now | 180.9% | Piper Sandler | Joseph Catanzaro43% | $19 → $10 | Downgrade | Overweight → Neutral | Get Alert |
| 06/28/2024 | Buy Now | 798.88% | HC Wainwright & Co. | Joseph Pantginis45% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | 546.07% | JMP Securities | Reni Benjamin46% | $25 → $23 | Maintains | Market Outperform | Get Alert |
| 06/03/2024 | Buy Now | 798.88% | HC Wainwright & Co. | Joseph Pantginis45% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2024 | Buy Now | 798.88% | HC Wainwright & Co. | Joseph Pantginis45% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 798.88% | HC Wainwright & Co. | Joseph Pantginis45% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 798.88% | HC Wainwright & Co. | Joseph Pantginis45% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 433.71% | Piper Sandler | Joseph Catanzaro43% | $18 → $19 | Maintains | Overweight | Get Alert |
| 03/07/2024 | Buy Now | 630.34% | Truist Securities | Asthika Goonewardene41% | $17 → $26 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 798.88% | HC Wainwright & Co. | Joseph Pantginis45% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 602.25% | Wells Fargo | Yanan Zhu36% | $22 → $25 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 798.88% | HC Wainwright & Co. | Joseph Pantginis45% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 489.89% | Goldman Sachs | Andrea Tan40% | $19 → $21 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 517.98% | Barclays | Peter Lawson42% | $18 → $22 | Maintains | Overweight | Get Alert |
| 02/21/2024 | Buy Now | 433.71% | Goldman Sachs | Andrea Tan40% | $13 → $19 | Maintains | Buy | Get Alert |
| 02/20/2024 | Buy Now | 602.25% | JMP Securities | Reni Benjamin46% | $18 → $25 | Maintains | Market Outperform | Get Alert |
| 02/20/2024 | Buy Now | 517.98% | Wells Fargo | Yanan Zhu36% | $17 → $22 | Maintains | Overweight | Get Alert |
| 02/20/2024 | Buy Now | 433.71% | Goldman Sachs | Andrea Tan40% | $13 → $19 | Maintains | Buy | Get Alert |
| 02/20/2024 | Buy Now | 405.62% | Piper Sandler | Joseph Catanzaro43% | $14 → $18 | Maintains | Overweight | Get Alert |
| 02/20/2024 | Buy Now | 855.06% | Chardan Capital | Geulah Livshits45% | $29 → $34 | Maintains | Buy | Get Alert |
| 12/27/2023 | Buy Now | 686.52% | HC Wainwright & Co. | Joseph Pantginis45% | $38 → $28 | Maintains | Buy | Get Alert |
| 12/27/2023 | Buy Now | 377.53% | Truist Securities | Asthika Goonewardene41% | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | Buy Now | 237.08% | Goldman Sachs | Andrea Tan40% | → $12 | Initiates | → Buy | Get Alert |
| 11/08/2023 | Buy Now | 686.52% | HC Wainwright & Co. | Joseph Pantginis45% | $38 → $28 | Maintains | Buy | Get Alert |
| 09/18/2023 | Buy Now | 405.62% | Barclays | Peter Lawson42% | $40 → $18 | Maintains | Overweight | Get Alert |
| 09/15/2023 | Buy Now | 377.53% | Truist Securities | Asthika Goonewardene41% | → $17 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 742.7% | Mizuho | Mara Goldstein57% | → $30 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 602.25% | Stifel | Benjamin Burnett46% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 405.62% | JMP Securities | Reni Benjamin46% | → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/15/2023 | Buy Now | 967.42% | HC Wainwright & Co. | Joseph Pantginis45% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 602.25% | Stifel | Benjamin Burnett46% | $27 → $25 | Maintains | Buy | Get Alert |
| 08/17/2023 | Buy Now | 405.62% | JMP Securities | Reni Benjamin46% | → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/16/2023 | Buy Now | 714.61% | Chardan Capital | Geulah Livshits45% | $29 → $29 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 714.61% | Chardan Capital | Geulah Livshits45% | → $29 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 967.42% | HC Wainwright & Co. | Joseph Pantginis45% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 377.53% | Truist Securities | Asthika Goonewardene41% | → $17 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 714.61% | Chardan Capital | Geulah Livshits45% | → $29 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2023 | Buy Now | 967.42% | HC Wainwright & Co. | Joseph Pantginis45% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2023 | Buy Now | 742.7% | Mizuho | Mara Goldstein57% | → $30 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | Buy Now | 742.7% | Mizuho | Mara Goldstein57% | → $30 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | 967.42% | HC Wainwright & Co. | Joseph Pantginis45% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | Buy Now | 405.62% | JMP Securities | Reni Benjamin46% | → $18 | Reiterates | → Market Outperform | Get Alert |
| 05/30/2023 | Buy Now | 377.53% | Wells Fargo | Yanan Zhu36% | $11 → $17 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/30/2023 | Buy Now | 405.62% | JMP Securities | Reni Benjamin46% | → $18 | Reinstates | Market Outperform → Market Perform | Get Alert |
| 05/30/2023 | Buy Now | 574.16% | Stifel | Benjamin Burnett46% | $21 → $24 | Maintains | Buy | Get Alert |
| 05/30/2023 | Buy Now | 714.61% | Chardan Capital | Geulah Livshits45% | → $29 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2023 | Buy Now | 967.42% | HC Wainwright & Co. | Joseph Pantginis45% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2023 | Buy Now | 489.89% | Stifel | Benjamin Burnett46% | $21 → $21 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | 546.07% | Baird | Michael Ulz61% | $20 → $23 | Maintains | Outperform | Get Alert |
| 05/11/2023 | Buy Now | 489.89% | Stifel | Benjamin Burnett46% | → $21 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 461.8% | Baird | Michael Ulz61% | $25 → $20 | Maintains | Outperform | Get Alert |
| 03/27/2023 | Buy Now | 208.99% | Wells Fargo | Yanan Zhu36% | → $11 | Assumes | → Equal-Weight | Get Alert |
| 03/27/2023 | Buy Now | 967.42% | HC Wainwright & Co. | Joseph Pantginis45% | → $38 | Reiterates | → Buy | Get Alert |
| 03/06/2023 | Buy Now | 208.99% | Wells Fargo | Adam Shine63% | $14 → $11 | Maintains | Equal-Weight | Get Alert |
| 03/01/2023 | Buy Now | 321.35% | Oppenheimer | Mark Breidenbach48% | $25 → $15 | Maintains | Outperform | Get Alert |
| 03/01/2023 | Buy Now | 714.61% | Chardan Capital | Geulah Livshits45% | → $29 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 967.42% | HC Wainwright & Co. | Joseph Pantginis45% | → $38 | Reiterates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | 293.26% | Piper Sandler | Joseph Catanzaro43% | $11 → $14 | Upgrade | Neutral → Overweight | Get Alert |
| 01/24/2023 | Buy Now | 377.53% | Truist Securities | Asthika Goonewardene41% | $16 → $17 | Maintains | Buy | Get Alert |
| 12/09/2022 | Buy Now | 68.54% | Goldman Sachs | Madhu Kumar72% | $20 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 12/09/2022 | Buy Now | 68.54% | Benchmark | Madhu Kumar72% | $20 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 11/21/2022 | Buy Now | 489.89% | JMP Securities | Reni Benjamin46% | $25 → $21 | Maintains | Market Outperform | Get Alert |
| 11/21/2022 | Buy Now | 208.99% | Piper Sandler | Joseph Catanzaro43% | $13 → $11 | Maintains | Neutral | Get Alert |
| 11/21/2022 | Buy Now | 714.61% | Chardan Capital | Geulah Livshits45% | $30 → $29 | Maintains | Buy | Get Alert |
| 11/18/2022 | Buy Now | 967.42% | HC Wainwright & Co. | Joseph Pantginis45% | $43 → $38 | Maintains | Buy | Get Alert |
| 10/31/2022 | Buy Now | — | Guggenheim | Kelsey Goodwin34% | — | Initiates | → Neutral | Get Alert |
| 08/10/2022 | Buy Now | 574.16% | Stifel | Benjamin Burnett46% | → $24 | Maintains | Buy | Get Alert |
| 08/05/2022 | Buy Now | 602.25% | Baird | Michael Ulz61% | $34 → $25 | Maintains | Outperform | Get Alert |
| 07/01/2022 | Buy Now | 405.62% | Goldman Sachs | Madhu Kumar72% | $64 → $18 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | 265.17% | Stifel | Benjamin Burnett46% | $26 → $13 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | 658.43% | Oppenheimer | Mark Breidenbach48% | $31 → $27 | Maintains | Outperform | Get Alert |
| 05/27/2022 | Buy Now | 770.79% | Chardan Capital | Geulah Livshits45% | $44 → $31 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | 265.17% | Piper Sandler | Joseph Catanzaro43% | $20 → $13 | Maintains | Neutral | Get Alert |
| 05/24/2022 | Buy Now | 1697.75% | Goldman Sachs | Madhu Kumar72% | $79 → $64 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | 630.34% | Stifel | Benjamin Burnett46% | → $26 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Iovance Biotherapeutics (IOVA) stock?
The latest price target for Iovance Biotherapeutics (NASDAQ:IOVA) was reported by Goldman Sachs on April 17, 2025. The analyst firm set a price target for $16.00 expecting IOVA to rise to within 12 months (a possible 349.44% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Iovance Biotherapeutics (IOVA)?
The latest analyst rating for Iovance Biotherapeutics (NASDAQ:IOVA) was provided by Goldman Sachs, and Iovance Biotherapeutics maintained their buy rating.
When was the last upgrade for Iovance Biotherapeutics (IOVA)?
The last upgrade for Iovance Biotherapeutics Inc happened on May 30, 2023 when Wells Fargo raised their price target to $17. Wells Fargo previously had an equal-weight for Iovance Biotherapeutics Inc.
When was the last downgrade for Iovance Biotherapeutics (IOVA)?
The last downgrade for Iovance Biotherapeutics Inc happened on July 29, 2024 when Piper Sandler changed their price target from $19 to $10 for Iovance Biotherapeutics Inc.
When is the next analyst rating going to be posted or updated for Iovance Biotherapeutics (IOVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Iovance Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Iovance Biotherapeutics was filed on April 17, 2025 so you should expect the next rating to be made available sometime around April 17, 2026.
Is the Analyst Rating Iovance Biotherapeutics (IOVA) correct?
While ratings are subjective and will change, the latest Iovance Biotherapeutics (IOVA) rating was a maintained with a price target of $18.00 to $16.00. The current price Iovance Biotherapeutics (IOVA) is trading at is $3.56, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
